No evidence of association between functional polymorphisms located within IL6R and IL6ST genes and systemic sclerosis

Tissue Antigens

Volumn 80, Issue 3, 2012, Pages 254-258

  Cenit M C ^a   Simeon C P ^b   Fonollosa, V ^b   Espinosa, G ^c   Beltran E ^d   Saez Comet L ^e   Vicente Rabaneda, E ^f   Garcia Hernandez F J ^g   Martinez Estupinan L ^h   Rodriguez Carballeira M ⁱ   Hernandez V ^j   de la Pena P G ^k   Fernandez Castro M ^l   Narvaez F J ⁱ   Pros, A ^m   Gallego, M ⁿ   Rios Fernandez R ^o   Camps, M T ^p   Fernandez Nebro A ^p   Egurbide, M V ^q   Carreira, P ^r   Gonzalez Gay M A ^s   Martin J ^a   more..

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^e HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^f HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

ⁱ HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^j HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^k Hospital Universitario Madrid Norte Sanchinarro   (Spain)

^l HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^m HOSPITAL DEL MAR   (Spain)

ⁿ HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^o HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^p HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^q HOSPITAL DE CRUCES   (Spain)

^r HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^s HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

more..

Author keywords

Genetic association study; IL6R; IL6ST; Interleukin 6; Polymorphisms; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; INTERLEUKIN 6 RECEPTOR;

ARTICLE; AUTOIMMUNE DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE PREDISPOSITION; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; IL6R GENE; IL6ST GENE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; RISK; SYSTEMIC SCLEROSIS;

CASE-CONTROL STUDIES; CYTOKINE RECEPTOR GP130; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, INTERLEUKIN-6; SCLERODERMA, SYSTEMIC;

EID: 84864823236     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2012.01915.x     Document Type: Article

References (29)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009: 360: 1989-2003.
2. Martin JE, Bossini-Castillo L, Martin J. Unraveling the genetic component of systemic sclerosis. Hum Genet 2012:131: 1023-37.
3. Kishimoto T. Interleukin-6: from basic science to medicine-40years in immunology. Annu Rev Immunol. 2005: 23: 1-21.
4. Barnes TC, Anderson ME, Moots RJ. The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int J Rheumatol 2011: 2011: 721608.
5. Fishman D, Faulds G, Jeffery R et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998: 102: 1369-76.
6. Beretta L, Santaniello A, Cappiello F, Barili M, Scorza R. No evidence for a role of the proximal IL-6G/C -174 single nucleotide polymorphism in Italian patients with systemic sclerosis. J Cell Mol Med 2007: 11: 896-8.
7. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 2001: 15: 43-58.
8. Salvi M, Girasole G, Pedrazzoni M et al. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease. J Clin Endocrinol Metab 1996: 81: 2976-9.
9. Mitsuyama K, Toyonaga A, Sasaki E et al. Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut 1995: 36: 45-9.
10. Padberg F, Feneberg W, Schmidt S et al. CSF and serum levels of soluble interleukin-6 receptors (sIL-6R and sgp130), but not of interleukin-6 are altered in multiple sclerosis. J Neuroimmunol 1999: 99: 218-23.
11. Mullberg J, Oberthur W, Lottspeich F et al. The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J Immunol 1994: 152: 4958-68.
12. Hamid YH, Urhammer SA, Jensen DP et al. Variation in the interleukin-6 receptor gene associates with type 2 diabetes in Danish whites. Diabetes 2004: 53: 3342-5.
13. Qi L, Rifai N, Hu FB. Interleukin-6 receptor gene variations, plasma interleukin-6 levels, and type 2 diabetes in U.S. Women. Diabetes 2007: 56: 3075-81.
14. Rodriguez-Rodriguez L, Lamas JR, Varade J et al. Plasma soluble IL-6 receptor concentration in rheumatoid arthritis: associations with the rs8192284 IL6R polymorphism and with disease activity. Rheumatol Int 2011: 31: 409-13.
15. Hasegawa M, Sato S, Ihn H, Takehara K. Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology (Oxford) 1999: 38: 612-17.
16. Benrick A, Jirholt P, Wernstedt I et al. A non-conservative polymorphism in the IL-6 signal transducer (IL6ST)/gp130 is associated with myocardial infarction in a hypertensive population. Regul Pept 2008: 146: 189-96.
17. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980: 23: 581-90.
18. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988: 15: 202-5.
19. Purcell S, Neale B, Todd-Brown K et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007: 81: 559-75.
20. Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet 2006: 38: 209-13.
21. Dema B, Martinez A, Fernandez-Arquero M et al. The IL6-174G/C polymorphism is associated with celiac disease susceptibility in girls. Hum Immunol 2009: 70: 191-4.
22. Leroy EC, Smith EA, Kahaleh MB, Trojanowska M, Silver RM. A strategy for determining the pathogenesis of systemic sclerosis. Is transforming growth factor beta the answer? Arthritis Rheum 1989: 32: 817-25.
23. Duncan MR, Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 1991: 97: 686-92.
24. Zhernakova A, van Diemen CC, Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet 2009: 10: 43-55.
25. Fenoglio D, Battaglia F, Parodi A et al. Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. Clin Immunol 2011: 139: 249-57.
26. Deleuran B, Abraham DJ. Possible implication of the effector CD4+ T-cell subpopulation TH17 in the pathogenesis of systemic scleroderma. Nat Clin Pract Rheumatol 2007: 3: 682-3.
27. Shima Y, Kuwahara Y, Murota H et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 2010: 49: 2408-12.
28. Radstake TR, Gorlova O, Rueda B et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 2010: 42: 426-9.
29. Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet 2007: 39: 906-13.